中国医药
中國醫藥
중국의약
CHINA MEDICINE
2010年
9期
785-787
,共3页
尹作民%李长江%王燕%刘为生%滕军
尹作民%李長江%王燕%劉為生%滕軍
윤작민%리장강%왕연%류위생%등군
心肌梗死%骨髓祖代细胞%干细胞移植%心脏功能试验
心肌梗死%骨髓祖代細胞%榦細胞移植%心髒功能試驗
심기경사%골수조대세포%간세포이식%심장공능시험
Myocardial infarction%Myeloid progenitor cells%Stemcell transplantation%Heart function tests
目的 探讨自体骨髓干细胞冠状动脉内移植对急性心肌梗死患者心功能的影响.方法 因急性心肌梗死住院并行介入治疗的患者38例,按照完全随机分组的原则分为干细胞移植治疗组18例和对照组20例,干细胞移植治疗组患者在心肌梗死发生14 d后进行冠状动脉内注射自体骨髓干细胞治疗.术前1周和术后6个月时,采用99Tcm-MIBI心肌灌注显像、二维超声心动图评价患者心肌灌注、左心室射血分数.结果 干细胞移植治疗组与对照组比较,自体骨髓干细胞移植前2组间心肌灌注(2.1±0.1比2.2±0.2,P=0.76)和左心室射血分数(0.45±0.13比0.41±0.22,P=0.56)差异无统计学意义,术后6个月时干细胞移植治疗组心肌灌注明显好于对照组(1.5±0.2比2.3±0.4,P=0.04),左心室射血分数高于对照组(0.55±0.12比0.44±0.24,P=0.03),再梗死发生率、再次血运重建率和病死率2组间差异无统计学意义(P＞0.05),而心力衰竭的发生率干细胞移植治疗组低于对照组(5.5%比35.0%,P=0.03).结论 自体骨髓干细胞冠状动脉内移植可以改善急性心肌梗死患者的心功能,减少心力衰竭的发生.
目的 探討自體骨髓榦細胞冠狀動脈內移植對急性心肌梗死患者心功能的影響.方法 因急性心肌梗死住院併行介入治療的患者38例,按照完全隨機分組的原則分為榦細胞移植治療組18例和對照組20例,榦細胞移植治療組患者在心肌梗死髮生14 d後進行冠狀動脈內註射自體骨髓榦細胞治療.術前1週和術後6箇月時,採用99Tcm-MIBI心肌灌註顯像、二維超聲心動圖評價患者心肌灌註、左心室射血分數.結果 榦細胞移植治療組與對照組比較,自體骨髓榦細胞移植前2組間心肌灌註(2.1±0.1比2.2±0.2,P=0.76)和左心室射血分數(0.45±0.13比0.41±0.22,P=0.56)差異無統計學意義,術後6箇月時榦細胞移植治療組心肌灌註明顯好于對照組(1.5±0.2比2.3±0.4,P=0.04),左心室射血分數高于對照組(0.55±0.12比0.44±0.24,P=0.03),再梗死髮生率、再次血運重建率和病死率2組間差異無統計學意義(P＞0.05),而心力衰竭的髮生率榦細胞移植治療組低于對照組(5.5%比35.0%,P=0.03).結論 自體骨髓榦細胞冠狀動脈內移植可以改善急性心肌梗死患者的心功能,減少心力衰竭的髮生.
목적 탐토자체골수간세포관상동맥내이식대급성심기경사환자심공능적영향.방법 인급성심기경사주원병행개입치료적환자38례,안조완전수궤분조적원칙분위간세포이식치료조18례화대조조20례,간세포이식치료조환자재심기경사발생14 d후진행관상동맥내주사자체골수간세포치료.술전1주화술후6개월시,채용99Tcm-MIBI심기관주현상、이유초성심동도평개환자심기관주、좌심실사혈분수.결과 간세포이식치료조여대조조비교,자체골수간세포이식전2조간심기관주(2.1±0.1비2.2±0.2,P=0.76)화좌심실사혈분수(0.45±0.13비0.41±0.22,P=0.56)차이무통계학의의,술후6개월시간세포이식치료조심기관주명현호우대조조(1.5±0.2비2.3±0.4,P=0.04),좌심실사혈분수고우대조조(0.55±0.12비0.44±0.24,P=0.03),재경사발생솔、재차혈운중건솔화병사솔2조간차이무통계학의의(P＞0.05),이심력쇠갈적발생솔간세포이식치료조저우대조조(5.5%비35.0%,P=0.03).결론 자체골수간세포관상동맥내이식가이개선급성심기경사환자적심공능,감소심력쇠갈적발생.
Objective To investigate the effect of intracoronary transplantation of autologous bone marrow mesenchymal stem cell on left ventricular function in patients with acute myocardial infarction. Methods After successful percutaneous coronary intervention( PCI) for acute myocardial infarction, 38 patients were randomly assigned to either a control group ( n = 20) that received optimum postinfarction medical treatment, or a bone-marrow-cell group(n = 18) that received optimum medical treatment and intracoronary transfer of autologous bone-marrow cells 14 days after PCI. Data about myocardial perfusion imaging and left ventricular ejection fraction ( LVEF) were obtained by SPECT and echocardiogram, respectively, before and at 6 months' follow-up. Results There was no significant difference between the two groups in myocardial perfusion imaging and left ventricular ejection fraction befor intracoronary transplantation of autologous bone marrow stem cell(2. 1 ±0. 1 vs 2. 2±0. 2, P = 0. 76 and 0. 45 ±0.13 vs 0.41 ±0.22, P = 0. 56). After 6 months, SPECT myocardial perfusion was better in treated patients(1.5 ±0.2 vs 2.3±0.4, P=0.04) and LVEF improved significantly(0.55 ±0. 12 vs 0. 44 ±0.24, P=0.03) compared with the control. The incidence of heart failure in patients accepted inracoronary transplantation of autologous bone marrow stem cell was significantly decreased(5.5% vs 35.0% , P = 0. 03), though there was no significant difference in re-infarcion, re-myocardial perfusion and death. Conclusion The left ventricular function can be improved and the heart failure can be decreased by intracoronary transplantation of autologous bone marrow stem cell in patients with acute myocardial infarction.
